Johansen J S, Riis B J, Delmas P D, Christiansen C
Department of Clinical Chemistry, University of Copenhagen, Glostrup Hospital, Denmark.
Eur J Clin Invest. 1988 Apr;18(2):191-5. doi: 10.1111/j.1365-2362.1988.tb02412.x.
One hundred and ninety-one healthy early postmenopausal women, aged 45-54 years, were randomized to 2 years of treatment with (a) percutaneous 17 beta-oestradiol combined with progesterone (n = 29) or placebo (n = 28); (b) oral oestradiol valerate combined with cyproterone acetate (n = 37) or placebo (n = 39); (c) 24R, 25 (OH)2D3 (n = 29) or placebo (n = 29). We measured the plasma bone Gla-protein (BGP), bone mineral content of the proximal forearms (BMC), bone mineral density in the spine (BMDspine) and total body bone mineral (TBBM) in all the women before, and during, the study. In the groups of women receiving the oestrogen preparations, the plasma BGP decreased highly significantly (P less than 0.001) to a premenopausal level. The initial plasma BGP concentration was significantly related to the loss of BMC (P less than 0.001) in the placebo groups. The changes in plasma BGP were an indicator of the oestrogen response on BMC. We conclude that serial determinations of plasma BGP are useful for determination of the effect of oestrogen therapy in groups of patients, and that plasma BGP measured at the time of the menopause indicates what the rate of bone loss will be.
191名年龄在45至54岁之间的健康绝经早期女性被随机分为三组，接受为期两年的治疗：（a）经皮17β - 雌二醇联合孕酮（n = 29）或安慰剂（n = 28）；（b）戊酸雌二醇联合醋酸环丙孕酮（n = 37）或安慰剂（n = 39）；（c）24R, 25（OH）2D3（n = 29）或安慰剂（n = 29）。在研究前及研究期间，我们测量了所有女性的血浆骨钙素（BGP）、前臂近端骨矿物质含量（BMC）、脊柱骨矿物质密度（BMDspine）和全身骨矿物质（TBBM）。在接受雌激素制剂治疗的女性组中，血浆BGP显著降低（P < 0.001）至绝经前水平。在安慰剂组中，初始血浆BGP浓度与BMC的丢失显著相关（P < 0.001）。血浆BGP的变化是雌激素对BMC反应的一个指标。我们得出结论，连续测定血浆BGP有助于确定雌激素治疗对患者群体的效果，并且绝经时测量的血浆BGP表明骨丢失的速率。
